Abstract
Importance The coronavirus disease 2019 (COVID-19) pandemic has placed unprecedented stress on health systems across the world, and reliable estimates of risk for adverse hospital outcomes are needed.
Objective To quantify admission laboratory and comorbidity features associated with critical illness and death and mortality risk across 6 Eastern Massachusetts hospitals.
Design Retrospective cohort study using hospital course, prior diagnoses, and laboratory values through June 5, 2020.
Setting Emergency department and inpatient settings from 2 academic medical centers and 4 community hospitals.
Participants All individuals with hospital admission and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing across these 6 hospitals.
Main Outcome or Measure severe illness defined by ICU admission, mechanical ventilation, or death.
Results Among 2,511 hospitalized individuals who tested positive for SARS-CoV-2, 215 (8.6%) were eventually admitted to the ICU, 164 (6.5%) required mechanical ventilation, and 292 (11.6%) died. L1-regression models developed in 3 of these hospitals yielded area under ROC curve (AUC) of 0.823 for severe illness and 0.847 for mortality in the 3 held-out hospitals. In total, 78% of deaths occurred in the highest-risk mortality quintile.
Conclusions and Relevance Specific admission laboratory studies in concert with sociodemographic features and prior diagnosis facilitate risk stratification among individuals hospitalized for COVID-19.
Funding 1R56MH115187-01
Trial Registration None
Question How well can sociodemographic features, laboratory values, and comorbiditeis of individuals hospitalized with coronavirus disease 2019 (COVID-19) in Eastern Massachusetts through June 5, 2020 predict severe illness course?
Findings Among 2,511 hospitalized individuals who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and were admitted to one of six hospitals, 215 (8.6%) were eventually admitted to the ICU, 164 (6.5%) required mechanical ventilation, and 292 (11.6%) died. In a risk prediction model, 78% of deaths occurred in the top mortality-risk quintile.
Meaning Simple prediction models may assist in risk stratification among hospitalized COVID-19 patients.
Competing Interest Statement
Funding: 1R56MH115187-01. Dr. Perlis has received consulting fees from Burrage Capital, Genomind, RID Ventures, and Takeda. He holds equity in Outermost Therapeutics and Psy Therapeutics. Mr. Castro reports no conflict of interest.
Funding Statement
Funding: 1R56MH115187-01
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Partners HealthCare Human Research Committee. No participant contact was required in this study which relied on secondary use of data produced by routine clinical care, allowing waiver of requirement for informed consent as detailed by 45 CFR 46.116.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
IRB approval does not allow for sharing of data outside of health system
